A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab

We report a case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis (RA) who received tocilizumab. A 65-year-old woman with a 20-year history of RA participated in a tocilizumab clinical trial. She received a single dose of 8 mg/kg tocilizumab intravenously. The following day the patient started to experience numbness and purpura in all four extremities. The purpura of her left lower limb became necrotic, and a skin ulcer appeared 3 weeks later. Steroid-pulse treatment was initiated 12 weeks after tocilizumab administration, with the result that the numbness improved, and the skin ulcers showed complete epithelialization.

[1]  D. M. van der Heijde,et al.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.

[2]  M. Bandt,et al.  Vasculitides induced by TNFα antagonists: a study in 39 patients in France , 2006 .

[3]  S. Tominaga,et al.  Exacerbation of chronic active Epstein–Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody , 2006, Annals of the rheumatic diseases.

[4]  P. Emery,et al.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.

[5]  N. Nishimoto.  Interleukin-6 in rheumatoid arthritis , 2006, Current opinion in rheumatology.

[6]  P. Dieudé,et al.  Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. , 2004, The Journal of rheumatology.

[7]  M. Braun,et al.  Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. , 2004, The Journal of rheumatology.

[8]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[9]  P. Emery,et al.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. , 2003, The Journal of rheumatology.

[10]  D. Schmitt,et al.  Overexpression of circulating vascular endothelial growth factor (VEGF) in leukocytoclastic vasculitis , 1999, Archives of Dermatological Research.

[11]  O. Eickelberg,et al.  Hypoxia-induced interleukin-6 and interleukin-8 production is mediated by platelet-activating factor and platelet-derived growth factor in primary human lung cells. , 1998, American journal of respiratory cell and molecular biology.